Localized cutaneous fibrosing disorders.

Rheum Dis Clin North Am 2013 May 16;39(2):347-64. Epub 2013 Mar 16.

Division of Immunology and Rheumatology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA.

This article acquaints the reader with disorders of the skin that might mimic systemic sclerosis but whose pathology is localized to the skin and/or has extracutaneous manifestations that are different than systemic sclerosis. These disorders include localized scleroderma (morphea), eosinophilic fasciitis, scleredema, scleromyxedema, nephrogenic systemic fibrosis, and chronic graft-versus-host disease. Particular emphasis is placed on clinical and histopathologic features that help the clinician differentiate between these disorders. Treatment options are briefly reviewed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rdc.2013.02.013DOI Listing
May 2013
Get 20% Off Journals at LWW.com

Similar Publications

COVID-19 infection during autoimmune disease: study of 2 cases in Republic of Guinea.

Pan Afr Med J 2020 1;35(Suppl 2):96. Epub 2020 Jul 1.

Rheumatology Department, Maradi National Hospital, Maradi, Niger.

Introduction: Coronavirus is a virus that can target the respiratory, musculoskeletal systems with a cascade of inflammatory processes. The objective of this work is to establish the link between autoimmune diseases and a COVID-19 infection in Guinea.

Methods: Retrospective patient data were obtained from medical records. Read More

View Article and Full-Text PDF

HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis.

Arthritis Res Ther 2021 Feb 23;23(1):62. Epub 2021 Feb 23.

Servicio de Reumatología, Hospital Universitario de Canarias, C/Ofra s/n, 38320, Santa Cruz de Tenerife, Spain.

Objective: It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients with respect to controls and whether these changes were associated with disease-related data. Read More

View Article and Full-Text PDF
February 2021

Prostanoids in scleroderma microangiopathy: clinical and pharmacoeconomic comparison between two intravenous regimens.

Scand J Rheumatol 2021 Feb 24:1-7. Epub 2021 Feb 24.

Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

: Intravenous iloprost (ILO) has widely demonstrated its effectiveness and safety in systemic sclerosis (SSc) patients. Unfortunately, there is no clear consent about dosage, duration, frequency, and infusion modality. The aim of this study was to compare two different therapeutic schemes in the same cohort of consecutive SSc subjects, evaluating differences in terms of effectiveness [digital ulcer (DU) outcome], safety, and direct healthcare costs. Read More

View Article and Full-Text PDF
February 2021

Extended treatment response to Imatinib in Rosai-Dorfman Disease.

Eur J Haematol 2021 Feb 23. Epub 2021 Feb 23.

Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, USA.

Rosai-Dorfman disease (RDD) is a rare non-Langerhans cell histiocytosis, which can be classified as either localized to the lymph nodes or with extra-nodal disease. It was first reported by Dr. Dorfman in 1969 in a landmark paper describing sinus histiocytosis with massive lymphadenopathy. Read More

View Article and Full-Text PDF
February 2021

Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity.

Mult Scler Relat Disord 2021 Feb 10;50:102831. Epub 2021 Feb 10.

Department of Rehabilitation, The National Hospital for Neurology & Neurosurgery, University College London Hospitals (UCLH), London.

Background: Spasticity is a common problematic symptom in Multiple Sclerosis with over one third of patients failing first line therapies. Intrathecal baclofen is a safe and efficacious option for treatment resistant spasticity. Anecdotally patients report improved concentration/cognitive performance when switching to intrathecal baclofen (ITB) from systemic medications. Read More

View Article and Full-Text PDF
February 2021